期刊
CANCER CELL
卷 40, 期 6, 页码 659-+出版社
CELL PRESS
DOI: 10.1016/j.ccell.2022.04.011
关键词
-
资金
- NIH [CA252009, CA243577, CA210181]
- Effie Marie Cain Fellowship
- Jean Shelby Fund for Cancer Research at Communities Foundation of Texas
- UT Southwestern TARDIS Physician-Scientist Fellowship - Burroughs Wellcome Fund
- Cancer Center Support Grant [P30 CA142543]
Recent studies have identified a unique population of cancer-associated fibroblasts (apCAFs) derived from mesothelial cells, which play a critical role in pancreatic cancer progression. These apCAFs directly induce naive CD4(+) T cells to differentiate into regulatory T cells (Tregs) in an antigen-specific manner.
Recent studies have identified a unique cancer-associated fibroblast (CAF) population termed antigen-presenting CAFs (apCAFs), characterized by the expression of major histocompatibility complex class II molecules, suggesting a function in regulating tumor immunity. Here, by integrating multiple single-cell RNA-sequencing studies and performing robust lineage-tracing assays, we find that apCAFs are derived from mesothelial cells. During pancreatic cancer progression, mesothelial cells form apCAFs by downregulating mesothelial features and gaining fibroblastic features, a process induced by interleukin-1 and transforming growth factor beta. apCAFs directly ligate and induce naive CD4(+) T cells into regulatory T cells (Tregs) in an antigen-specific manner. Moreover, treatment with an antibody targeting the mesothelial cell marker mesothelin can effectively inhibit mesothelial cell to apCAF transition and Treg formation induced by apCAFs. Taken together, our study elucidates how mesothelial cells may contribute to immune evasion in pancreatic cancer and provides insight on strategies to enhance cancer immune therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据